Pritchard Adam J, Mir Anis K, Dev Kumlesh K
Drug Development, School of Medicine, Trinity College Dublin, Dublin, Ireland.
Autoimmunity, Transplantation and Inflammatory Disease, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
PLoS One. 2014 Jun 9;9(6):e99444. doi: 10.1371/journal.pone.0099444. eCollection 2014.
The family of sphingosine-1-phosphate receptors (S1PRs) is G-protein-coupled, comprised of subtypes S1PR1-S1PR5 and activated by the endogenous ligand S1P. The phosphorylated version of Fingolimod (pFTY720), an oral therapy for multiple sclerosis (MS), induces S1PR1 internalisation in T cells, subsequent insensitivity to S1P gradients and sequestering of these cells within lymphoid organs, thus limiting immune response. S1PRs are also expressed in neuronal and glial cells where pFTY720 is suggested to directly protect against lysolecithin-induced deficits in myelination state in organotypic cerebellar slices. Of note, the effect of pFTY720 on immune cells already migrated into the CNS, prior to treatment, has not been well established. We have previously found that organotypic slice cultures do contain immune cells, which, in principle, could also be regulated by pFTY720 to maintain levels of myelin. Here, a mouse organotypic cerebellar slice and splenocyte co-culture model was thus used to investigate the effects of pFTY720 on splenocyte-induced demyelination. Spleen cells isolated from myelin oligodendrocyte glycoprotein immunised mice (MOG-splenocytes) or from 2D2 transgenic mice (2D2-splenocytes) both induced demyelination when co-cultured with mouse organotypic cerebellar slices, to a similar extent as lysolecithin. As expected, in vivo treatment of MOG-immunised mice with FTY720 inhibited demyelination induced by MOG-splenocytes. Importantly, in vitro treatment of MOG- and 2D2-splenocytes with pFTY720 also attenuated demyelination caused by these cells. In addition, while in vitro treatment of 2D2-splenocytes with pFTY720 did not alter cell phenotype, pFTY720 inhibited the release of the pro-inflammatory cytokines such as interferon gamma (IFNγ) and interleukin 6 (IL6) from these cells. This work suggests that treatment of splenocytes by pFTY720 attenuates demyelination and reduces pro-inflammatory cytokine release, which likely contributes to enhanced myelination state induced by pFTY720 in organotypic cerebellar slices.
鞘氨醇-1-磷酸受体(S1PRs)家族是G蛋白偶联受体家族,由S1PR1 - S1PR5亚型组成,并由内源性配体S1P激活。芬戈莫德(pFTY720)是一种用于治疗多发性硬化症(MS)的口服药物,其磷酸化形式可诱导T细胞中的S1PR1内化,随后使其对S1P梯度不敏感,并将这些细胞隔离在淋巴器官内,从而限制免疫反应。S1PRs也在神经元和神经胶质细胞中表达,有人认为pFTY720可直接保护器官型小脑切片免受溶血卵磷脂诱导的髓鞘形成状态缺陷的影响。值得注意的是,pFTY720对治疗前已迁移到中枢神经系统的免疫细胞的作用尚未明确。我们之前发现器官型切片培养物中确实含有免疫细胞,原则上这些细胞也可能受pFTY720调节以维持髓鞘水平。因此,在此使用小鼠器官型小脑切片和脾细胞共培养模型来研究pFTY720对脾细胞诱导的脱髓鞘作用的影响。从髓鞘少突胶质细胞糖蛋白免疫小鼠(MOG - 脾细胞)或2D2转基因小鼠(2D2 - 脾细胞)中分离的脾细胞与小鼠器官型小脑切片共培养时,均会诱导脱髓鞘,其程度与溶血卵磷脂相似。正如预期的那样,用FTY720对MOG免疫小鼠进行体内治疗可抑制MOG - 脾细胞诱导的脱髓鞘。重要的是,用pFTY720对MOG - 和2D2 - 脾细胞进行体外治疗也可减轻这些细胞引起的脱髓鞘。此外,虽然用pFTY720对2D2 - 脾细胞进行体外治疗不会改变细胞表型,但pFTY720可抑制这些细胞释放促炎细胞因子,如干扰素γ(IFNγ)和白细胞介素6(IL6)。这项工作表明,用pFTY720处理脾细胞可减轻脱髓鞘并减少促炎细胞因子的释放,这可能有助于增强pFTY720在器官型小脑切片中诱导的髓鞘形成状态。